Last updated: August 29, 2026
Aldara is the former branded version of imiquimod 5% cream, a topical immune-response modifier used primarily for actinic keratosis, superficial basal cell carcinoma, and external genital and perianal warts. Its commercial position has deteriorated since generic imiquimod entered the U.S. market. Aldara no longer has meaningful composition-of-matter or market exclusivity, and public-company filings do not provide a reliable standalone revenue series for the brand.
The market has shifted from branded dermatology sales to low-price generic competition. Current value is concentrated in generic imiquimod supply, private-label distribution, physician familiarity, and manufacturing scale rather than in the Aldara trademark or its historic patent estate.
What is Aldara and how does it compare with generic imiquimod?
Aldara is a topical cream containing imiquimod 5%. Imiquimod activates innate immune signaling, including Toll-like receptor 7 pathways, and promotes local cytokine production. It is not a conventional cytotoxic drug and is not a biologic.
| Product |
Active ingredient |
Strength |
Dosage form |
Main U.S. indications |
Current market position |
| Aldara |
Imiquimod |
5% |
Topical cream, single-use packets |
Actinic keratosis, superficial BCC, external genital and perianal warts |
Legacy brand; generic competition |
| Generic imiquimod |
Imiquimod |
5% |
Topical cream, packets or tubes depending on product |
Same or substantially similar approved indications |
Primary U.S. volume source |
| Zyclara |
Imiquimod |
2.5% and 3.75% |
Topical cream |
Actinic keratosis |
Separate branded formulation, limited differentiation |
| Other topical therapies |
Various |
Various |
Creams, gels, solutions |
Actinic keratosis and related dermatologic conditions |
Competing treatment class |
Aldara was originally commercialized by 3M Pharmaceuticals. Commercial rights subsequently moved through specialty-pharmaceutical ownership changes, including Graceway and Medicis-related assets. Valeant Pharmaceuticals, now Bausch Health, acquired Medicis in 2012. The ownership history complicates direct revenue comparisons because Aldara was reported within broader pharmaceutical portfolios rather than as a consistently disclosed product line.
When did Aldara lose exclusivity?
Aldara lost effective market exclusivity when U.S. generic imiquimod 5% products received FDA approval. The product’s principal patent protection has expired, and the brand does not have an active small-molecule exclusivity position that would block generic competition.
Aldara FDA milestones
| Milestone |
Date or status |
| Original U.S. FDA approval |
1997 |
| Active ingredient |
Imiquimod |
| Original NDA |
NDA 020723 |
| Initial approved strength |
5% cream |
| Generic approval pathway |
ANDA approval under Hatch-Waxman |
| Current exclusivity |
None of commercial significance |
| Biologic exclusivity |
Not applicable |
| Pediatric exclusivity |
Not a current commercial barrier |
| Orange Book status |
Historical listed patents have expired; current commercial protection is not patent-based |
The FDA approved Aldara in 1997 for external genital and perianal warts. The agency later approved it for actinic keratosis and superficial basal cell carcinoma. Those additional indications expanded the market but did not create durable exclusivity because method-of-use protection has also expired or has become commercially ineffective against approved generic products.[1]
What patents protected Aldara?
Aldara was protected by patents covering imiquimod-related chemistry, pharmaceutical compositions, and topical use. The relevant patent families were filed primarily in the 1980s and early 1990s. Their statutory terms have expired.
Patent categories associated with Aldara
| Patent category |
Commercial purpose |
Current status |
| Imidazoquinoline compound patents |
Protected imiquimod and related compounds |
Expired |
| Topical composition patents |
Covered cream formulations and delivery vehicles |
Expired |
| Treatment-method patents |
Covered use for genital warts, actinic keratosis, or superficial BCC |
Expired or commercially ineffective |
| Manufacturing patents |
Covered synthesis or processing routes |
Any relevant early patents have expired |
| Brand trademark |
Protected the Aldara name |
Trademark protection does not prevent generic imiquimod sales |
Aldara’s patent estate was materially weaker than the estates supporting modern specialty drugs because the underlying patents predated the product’s 1997 approval by many years. Patent-term restoration could extend an early-filed patent only to a limited degree, and the principal commercial barriers have now elapsed.
The Orange Book remains the relevant source for FDA-listed patents tied to the NDA. It should not be treated as evidence of current market exclusivity where listed patents have expired or no longer prevent ANDA approval.[2]
What is the Orange Book status of Aldara?
The Orange Book identifies Aldara as an approved drug product associated with imiquimod 5% cream. Its historical patent listings do not provide a current barrier to generic entry.
For commercial diligence, the important conclusions are:
- Aldara has no meaningful remaining small-molecule exclusivity.
- Expired patents do not support a new Paragraph IV litigation strategy.
- Generic applicants can rely on the reference listed drug’s safety and efficacy findings through the ANDA pathway.
- Any remaining differentiation must come from packaging, supply reliability, formulation convenience, channel access, or brand recognition.
A branded product may remain listed in FDA databases even after its economic exclusivity has ended. Listing status is not equivalent to active patent protection.
Which companies compete with Aldara and generic imiquimod?
The competitive field includes generic manufacturers, specialty dermatology companies, and alternative therapies.
Generic imiquimod suppliers
The U.S. generic market has included products from companies such as Teva, Perrigo, Taro, Glenmark, Amneal, and other ANDA holders or distributors, depending on product availability and labeling status. Supplier participation changes over time as companies enter, exit, transfer applications, or use contract manufacturing arrangements.
Competition is driven by:
- Wholesale acquisition price;
- Formulation and packet configuration;
- Pharmacy benefit manager placement;
- Retail and specialty-pharmacy coverage;
- Manufacturing capacity;
- Product availability during shortages;
- Contracting with dermatology and primary-care channels.
The market is generally fragmented at the supplier level but commoditized at the molecule level.
Alternative treatments
For actinic keratosis, alternatives include fluorouracil, diclofenac sodium gel, tirbanibulin, photodynamic therapy, and cryotherapy. For superficial basal cell carcinoma, excision, curettage and electrodessication, radiation, and other topical or procedural options compete with imiquimod. For external genital warts, podofilox, sinecatechins, cryotherapy, and surgical treatment are relevant alternatives.[3]
Aldara’s main advantage is its established clinical history and broad physician familiarity. Its disadvantages include local inflammatory reactions, prolonged treatment schedules, adherence burden, and the availability of lower-priced generic products.
How strong is the Aldara patent estate?
The Aldara patent estate is commercially weak. Its core weakness is not limited claim scope; it is expiration.
| Strength factor |
Assessment |
| Core compound protection |
Expired |
| Formulation protection |
Expired or nonblocking |
| Method-of-use protection |
Expired or nonblocking |
| Regulatory exclusivity |
Expired |
| Trademark |
Maintains brand identity but not molecule exclusivity |
| Manufacturing barriers |
Limited; imiquimod is an established small molecule |
| Generic substitution risk |
High |
| Biosimilar risk |
None |
A generic applicant does not need to reproduce the Aldara trademark, package design, or commercial presentation. It must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for a topical product. Once approved, the generic can compete directly with the branded product.
What Paragraph IV challenges affected Aldara?
Paragraph IV litigation was relevant during the original generic-entry period. ANDA applicants can challenge listed patents by certifying that a patent is invalid, unenforceable, or will not be infringed. That mechanism is no longer a significant commercial issue for Aldara because the relevant patent barriers have expired.
The key market event was generic approval and launch, not a current wave of patent litigation. Available public information does not indicate an active, material Paragraph IV dispute capable of restoring Aldara exclusivity.
Historical litigation and settlements involving Aldara-related patents should be interpreted in context. A settlement may have delayed entry at the time it was signed, but it has no continuing blocking effect after patent expiration.
What FDA regulatory status does Aldara have?
Aldara remains an FDA-approved reference product, subject to the regulatory status of its NDA and any current marketing arrangements. FDA approval does not guarantee ongoing commercial distribution. Brands can remain approved while manufacturers reduce production, discontinue certain package configurations, or rely on authorized distributors.
The principal FDA-regulated product characteristics are:
- Imiquimod 5% topical cream;
- Single-use packet presentation for the traditional Aldara product;
- Approved treatment regimens that vary by indication;
- Local immune-mediated adverse reactions;
- Generic products approved through ANDA pathways.
The FDA label warns of local skin reactions, including erythema, erosion, edema, flaking, scabbing, and crusting. The treatment schedule can require repeated application over multiple weeks, which affects adherence and substitution decisions.[1]
What formulations are protected by Aldara?
Aldara’s commercial formulation is imiquimod 5% cream. The cream vehicle and packet presentation were part of the product’s historic differentiation, but they do not create durable protection today.
Zyclara introduced lower-strength imiquimod formulations, including 2.5% and 3.75% cream, with different dosing schedules for actinic keratosis. Those products represented a formulation and regimen strategy rather than a new active ingredient. Any residual protection associated with those products must be assessed separately from Aldara’s expired 5% patent estate.
Formulation-based differentiation remains possible in topical dermatology, but a new product would need to demonstrate a meaningful clinical, tolerability, adherence, or convenience advantage. A minor vehicle change would face limited pricing power once prescribers and pharmacies can substitute generic imiquimod 5%.
How has Aldara’s revenue trajectory changed?
Aldara’s revenue trajectory followed the standard lifecycle for an older specialty dermatology product:
- Initial growth after FDA approval and indication expansion.
- Peak branded sales during the period when 5% imiquimod had limited direct competition.
- Decline after generic entry.
- Continued erosion from formulary substitution and lower generic pricing.
- Residual brand sales in selected channels, often supported by legacy prescribing or patient familiarity.
Public filings do not provide a consistent, standalone Aldara revenue line across the product’s ownership changes. 3M, Graceway, Medicis, and Valeant/Bausch Health reported portfolios at different levels of aggregation. As a result, historical Aldara revenue estimates from market-research providers should not be treated as audited company revenue.
Financial drivers
| Driver |
Effect on Aldara economics |
| Generic entry |
Major reduction in price and volume |
| Pharmacy substitution |
Redirects prescriptions away from the brand |
| Dermatology demand |
Supports ongoing molecule-level demand |
| Multiple indications |
Reduces dependence on one patient segment |
| Treatment duration |
Creates refill volume but can reduce adherence |
| Low manufacturing complexity |
Limits supplier pricing power |
| Brand recognition |
Preserves some residual demand but does not prevent substitution |
| Reimbursement |
Favors low-cost generic products |
| Alternative therapies |
Caps long-term volume growth |
The commercial value has therefore migrated from branded gross margin to generic unit economics. For manufacturers, imiquimod can remain attractive as a stable dermatology product with established demand, but it is unlikely to support the revenue or margin profile associated with a protected specialty drug.
What generic entry risks exist for Aldara?
Generic entry risk is effectively realized rather than prospective. The principal risks are:
- Continued brand-to-generic switching;
- Price compression as additional suppliers compete;
- Pharmacy benefit manager pressure;
- Retail substitution;
- Reduced physician attention to the Aldara name;
- Product discontinuation or reduced brand availability;
- Loss of formulary preference.
Generic supply risk is more relevant to patients and purchasers than patent risk. If a manufacturer exits, temporary shortages or wholesaler allocation can occur, but those events do not restore Aldara’s exclusivity. They can increase the value of reliable generic manufacturing and distribution.
Is there biosimilar risk for Aldara?
No. Aldara is a small-molecule topical drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competitive products are approved as generics, primarily through the ANDA pathway under the Federal Food, Drug, and Cosmetic Act.
The relevant competitive risks are generic substitution, topical bioequivalence requirements, formulation differences, and supply economics.
What licensing deals and ownership changes affected Aldara?
Aldara passed through several corporate ownership structures:
| Period |
Commercial owner or relevant company |
Strategic significance |
| Original launch period |
3M Pharmaceuticals |
Developed and commercialized Aldara |
| Specialty-pharma period |
Graceway Pharmaceuticals |
Held dermatology assets after 3M’s divestiture |
| Post-bankruptcy asset period |
Medicis and related entities |
Consolidated dermatology products |
| Post-2012 period |
Valeant Pharmaceuticals, later Bausch Health |
Acquired Medicis and its commercial portfolio |
These transactions transferred commercial rights and sales infrastructure. They did not reset patent expiration dates. An acquisition could improve distribution, contracting, or portfolio leverage, but it could not recreate molecule-level exclusivity.
What is the geographic coverage of Aldara?
Aldara and imiquimod have been marketed across major regulatory markets, including the United States, Europe, Canada, Australia, and other jurisdictions. Patent and regulatory status varies by country, but the product’s age means core exclusivity has generally expired in mature markets.
Commercial performance outside the United States depends on:
- National reimbursement;
- Prescription versus pharmacy-access rules;
- Local generic penetration;
- Tendering and distributor structure;
- Trademark ownership;
- Country-specific formulation approvals;
- Dermatology treatment patterns.
The United States remains the most important reference market for Orange Book and Paragraph IV analysis. European competition is governed by national and regional regulatory frameworks rather than the U.S. Orange Book.
What patent litigation affects Aldara today?
No active patent litigation appears to create a material barrier to generic imiquimod access. Any current disputes are more likely to concern product quality, labeling, supply, trademark use, distribution, or commercial contracts than enforceable core patents.
For diligence purposes, Aldara should be classified as:
- Patent-expired;
- Generic-exposed;
- Non-biologic;
- Low litigation risk on core product patents;
- High substitution risk;
- Low probability of exclusivity restoration.
How does Aldara compare with newer actinic keratosis drugs?
Aldara competes with newer products that offer shorter treatment courses, different tolerability profiles, or more convenient administration. Tirbanibulin, for example, uses a short five-day regimen for actinic keratosis, while imiquimod regimens can extend over several weeks depending on the indication.
| Attribute |
Aldara or generic imiquimod 5% |
Newer actinic keratosis products |
| Patent status |
Expired |
Often active or recently expired |
| Price |
Low for generics |
Generally higher |
| Treatment duration |
Longer, indication-dependent |
Often shorter |
| Clinical familiarity |
High |
Developing |
| Local reactions |
Common |
Product-specific |
| Reimbursement position |
Usually favorable |
Dependent on formulary access |
| Commercial growth |
Limited |
Potentially higher during exclusivity |
Aldara’s low cost protects molecule-level demand but limits revenue growth. Newer therapies can capture value through convenience and active patent estates rather than through lower pricing.
Key Takeaways
- Aldara is imiquimod 5% cream, originally developed and marketed by 3M.
- The product received FDA approval in 1997 and later gained approvals for actinic keratosis and superficial basal cell carcinoma.
- Core compound, formulation, and method-of-use protections have expired or no longer block generic competition.
- Generic imiquimod has displaced most branded Aldara volume in the United States.
- Aldara has no biosimilar risk because it is a small-molecule drug.
- Public filings do not support a reliable standalone Aldara revenue series across its ownership changes.
- Current economics favor low-cost generic suppliers, contract manufacturers, wholesalers, and pharmacy channels.
- The main commercial risks are price compression, substitution, supply changes, and competition from newer topical and procedural therapies.
- Current Aldara patent litigation does not appear to present a material barrier to generic entry.
- The product’s residual value is based on clinical familiarity and molecule-level demand, not exclusivity.
FAQs
Is Aldara still available in the United States?
Aldara’s commercial availability can vary by distributor and package configuration. Generic imiquimod 5% is the principal source of U.S. supply.
Is generic imiquimod as effective as Aldara?
FDA-approved generic imiquimod products must meet applicable pharmaceutical equivalence and bioequivalence requirements. Therapeutic outcomes depend on correct use, treatment adherence, and the clinical indication.
Can a company launch a new imiquimod cream without infringing Aldara patents?
Core Aldara patent protection has expired. A new product would still need FDA approval and would need to avoid infringement of any separately protected formulation, manufacturing, packaging, or device claims that remain enforceable.
Does Aldara have pediatric exclusivity?
No current pediatric exclusivity period materially limits generic imiquimod competition.
What is the investment case for generic imiquimod?
The investment case is based on stable dermatology demand, manufacturing efficiency, supply reliability, and distribution scale. It is not based on high branded pricing, patent protection, or exclusivity-driven margin expansion.
References
- U.S. Food and Drug Administration. (2023). Aldara (imiquimod) cream, 5% prescribing information. FDA/DailyMed.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Aldara, NDA 020723. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Imiquimod topical products. FDA.
- Bausch Health Companies Inc. (2012). Annual report and filings relating to the acquisition of Medicis Pharmaceutical Corporation. U.S. Securities and Exchange Commission.
